These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27393350)

  • 1. The effects of sequential treatments on hippocampal volumes in malignant glioma patients.
    Nolen SC; Lee B; Shantharam S; Yu HJ; Su L; Billimek J; Bota DA
    J Neurooncol; 2016 Sep; 129(3):433-441. PubMed ID: 27393350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
    Antoni D; Jastaniah Z; Haoming QC; Gaultier C; Ahle G; Couchot J; Atlani D; Schott R; Clavier JB; Srour R; Chaussemy D; Noël G
    Cancer Radiother; 2016 Jun; 20(4):282-91. PubMed ID: 27318555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation Dose-Dependent Hippocampal Atrophy Detected With Longitudinal Volumetric Magnetic Resonance Imaging.
    Seibert TM; Karunamuni R; Bartsch H; Kaifi S; Krishnan AP; Dalia Y; Burkeen J; Murzin V; Moiseenko V; Kuperman J; White NS; Brewer JB; Farid N; McDonald CR; Hattangadi-Gluth JA
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):263-269. PubMed ID: 28068234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of hippocampal location and radiation dose in glioblastoma patients with hippocampal atrophy.
    Le Fèvre C; Cheng X; Loit MP; Keller A; Cebula H; Antoni D; Thiery A; Constans JM; Proust F; Noel G
    Radiat Oncol; 2021 Jun; 16(1):112. PubMed ID: 34158078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
    Brandsma D; Stalpers L; Taal W; Sminia P; van den Bent MJ
    Lancet Oncol; 2008 May; 9(5):453-61. PubMed ID: 18452856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
    Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma.
    Narayana A; Golfinos JG; Fischer I; Raza S; Kelly P; Parker E; Knopp EA; Medabalmi P; Zagzag D; Eagan P; Gruber ML
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):383-9. PubMed ID: 18793954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irradiation and bevacizumab in high-grade glioma retreatment settings.
    Niyazi M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; Geisler J; la Fougère C; Ertl L; Linn J; Siefert A; Belka C
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):67-76. PubMed ID: 21030162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide.
    Yaman E; Buyukberber S; Benekli M; Oner Y; Coskun U; Akmansu M; Ozturk B; Kaya AO; Uncu D; Yildiz R
    Clin Neurol Neurosurg; 2010 Oct; 112(8):662-7. PubMed ID: 20627551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
    Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C
    J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
    Kumthekar P; Grimm S; Chandler J; Mehta M; Marymont M; Levy R; Muro K; Helenowski I; McCarthy K; Fountas L; Raizer J
    J Neurooncol; 2017 Jul; 133(3):589-594. PubMed ID: 28510787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive contralateral hippocampal atrophy following surgery for medically refractory temporal lobe epilepsy.
    Elliott CA; Gross DW; Wheatley BM; Beaulieu C; Sankar T
    Epilepsy Res; 2016 Sep; 125():62-71. PubMed ID: 27394376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
    Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
    J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged administration of temozolomide in adult patients with anaplastic glioma.
    Freyschlag CF; Smolczyk DR; Janzen E; Schmieder K; Thomé C; Lohr F; Wenz F; Weiss C; Tuettenberg J; Seiz M
    Anticancer Res; 2011 Nov; 31(11):3873-7. PubMed ID: 22110212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormalities in hippocampal volume of glioma patients prior to radiotherapy.
    Karunamuni RA; Seibert TM; White NS; McEvoy L; Farid N; Brewer J; Dale AM; McDonald CR; Hattangadi-Gluth JA
    Acta Oncol; 2017 Mar; 56(3):427-430. PubMed ID: 28156177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma.
    Yang TM; Wang HC; Lin YJ; Lin WC; Lu CH; Chang WN; Chang HW; Ho JT
    Surg Neurol; 2008 Dec; 70 Suppl 1():S1:60-3. PubMed ID: 19061770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current evidence of temozolomide and bevacizumab in treatment of gliomas.
    Nanegrungsunk D; Onchan W; Chattipakorn N; Chattipakorn SC
    Neurol Res; 2015 Feb; 37(2):167-83. PubMed ID: 25033940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.
    Douw L; Klein M; Fagel SS; van den Heuvel J; Taphoorn MJ; Aaronson NK; Postma TJ; Vandertop WP; Mooij JJ; Boerman RH; Beute GN; Sluimer JD; Slotman BJ; Reijneveld JC; Heimans JJ
    Lancet Neurol; 2009 Sep; 8(9):810-8. PubMed ID: 19665931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients.
    Niyazi M; Jansen NL; Rottler M; Ganswindt U; Belka C
    Radiat Oncol; 2014 Dec; 9():299. PubMed ID: 25529015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.
    Yamaguchi S; Hirata K; Toyonaga T; Kobayashi K; Ishi Y; Motegi H; Kobayashi H; Shiga T; Tamaki N; Terasaka S; Houkin K
    PLoS One; 2016; 11(12):e0167917. PubMed ID: 27936194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.